Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats

Bassani, Taysa Bervian; Gradowski, Raisa W.; Zaminelli, Tiago; Barbiero, Janaína K.; Santiago, Ronise Martins; Boschen, Suelen Lúcio; Cunha, Claúdio Ribeiro da; Lima, Marcelo M.S.; Andreatini, Roberto; Vital, Maria A.B.F.

doi:10.1016/j.brainres.2014.09.068

Cited by 63 publications

(37 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similarly, many but not all have shown benefits on measures of substantia nigra tyrosine hydroxylase or striatal dopamine compared to those not treated with melatonin [86][87][88][89][90][91][92]. While preclinical studies have engendered excitement about melatonin as a neuroprotective agent in PD [84], others have expressed concerns that melatonin may be neuroprotective in AD, but perhaps not in PD [18].…”

Section: What Is the Evidence That Melatonin Is Helpful In Animal Modmentioning

confidence: 99%

“…Animals models of PD (including rotenone, 6-hydroxydopamine (6-OHDA), and MPTP) have shown a benefit on motor function from melatonin in many [86][87][88][89], although not all [90,91], studies. Similarly, many but not all have shown benefits on measures of substantia nigra tyrosine hydroxylase or striatal dopamine compared to those not treated with melatonin [86][87][88][89][90][91][92].…”

Section: What Is the Evidence That Melatonin Is Helpful In Animal Modmentioning

confidence: 99%

See 1 more Smart Citation

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases

Trotti

Karroum

2016

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

In patients with neurodegenerative diseases, sleep disorders are common; they impair the quality of life for patients and caregivers and are associated with poorer clinical outcomes. Melatonin has circadian, hypnotic, and free radical-scavenging effects, and preclinical data suggest benefits of melatonin on neurodegeneration. However, randomized, controlled trials of melatonin in patients with neurodegenerative diseases have not shown strong effects. Trials in Alzheimer's patients demonstrate a lack of benefit on sleep quantity. Subjective measures of sleep quality are mixed, with possible symptomatic improvements seen only on some measures or at some time points. Benefits on cognition have not been observed across several studies. In Parkinson's patients, there may be minimal benefit on objective sleep measures, but a suggestion of subjective benefit in few, small studies. Effective treatments for the sleep disorders associated with neurodegenerative diseases are urgently needed, but current data are insufficient to establish melatonin as such a treatment.

show abstract

Section: What Is the Evidence That Melatonin Is Helpful In Animal Modmentioning

confidence: 99%

Section: What Is the Evidence That Melatonin Is Helpful In Animal Modmentioning

confidence: 99%

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases

Trotti

Karroum

2016

Curr Neurol Neurosci Rep

View full text Add to dashboard Cite

show abstract

“…These neurotoxins-based models are also useful for the screening of potential new treatments, including new agents aiming neuroprotection [184]. In this context, exogenous melatonin administration has demonstrated an outstanding neuroprotective effect in animal models of PD induced by different toxins such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl,1-1,2,3,6-tetrahydropyridine (MPTP), rotenone, paraquat, and maneb (Table 2) [132, 144, 161, 164]. …”

Section: Neuroprotective Potential Of Melatoninergic System In Parmentioning

confidence: 99%

“…Melatonin also inhibited apoptosis induced by rotenone by reducing the Bax expression and release of Omi/HtrA2 [204]. This neuroprotective effect of melatonin culminated in the prevention of motor deficits evoked by rotenone administration in rodents and in a Parkinsonism model in Drosophila melanogaster [159, 161, 162] (Table 2). …”

Section: Neuroprotective Potential Of Melatoninergic System In Parmentioning

confidence: 99%

Melatoninergic System in Parkinson’s Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms

Mack

Schamne

Sampaio

et al. 2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Melatonin is synthesized by several tissues besides the pineal gland, and beyond its regulatory effects in light-dark cycle, melatonin is a hormone with neuroprotective, anti-inflammatory, and antioxidant properties. Melatonin acts as a free-radical scavenger, reducing reactive species and improving mitochondrial homeostasis. Melatonin also regulates the expression of neurotrophins that are involved in the survival of dopaminergic neurons and reduces α-synuclein aggregation, thus protecting the dopaminergic system against damage. The unbalance of pineal melatonin synthesis can predispose the organism to inflammatory and neurodegenerative diseases such as Parkinson's disease (PD). The aim of this review is to summarize the knowledge about the potential role of the melatoninergic system in the pathogenesis and treatment of PD. The literature reviewed here indicates that PD is associated with impaired brain expression of melatonin and its receptors MT1 and MT2. Exogenous melatonin treatment presented an outstanding neuroprotective effect in animal models of PD induced by different toxins, such as 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, paraquat, and maneb. Despite the neuroprotective effects and the improvement of motor impairments, melatonin also presents the potential to improve nonmotor symptoms commonly experienced by PD patients such as sleep and anxiety disorders, depression, and memory dysfunction.

show abstract

“…The key symptoms of PD are tremors, rigidity, bradykinesia, postural instability, cognitive dysfunction, and sleep disturbance. These symptoms appeared due to progressive loss of dopaminergic neurons in substantia nigra pars compacta of brain, which further lead to loss of dopamine (DA) [2,3]. Another pathological hallmark of PD is the presence of eosinophilic intracytoplasmic proteinaceous inclusion bodies that are mainly composed of fibrillar α-synuclein termed Lewy bodies and dystrophic neurites (Lewy neurites) presents in surviving neurons [4].…”

Section: Introductionmentioning

confidence: 99%

Prediction of Anti-Parkinson Potential of Phytoconstituents Using Prediction of Activity Spectra of Substances Software

Kumar

Anand

et al. 2018

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: Neurodegenerative disorders are group of diseased conditions in which there is loss of neuron cells occur. The main objective of this study to find/search out the phytochemical with the help of prediction of activity spectra of substances (PASS), those show maximum activity over the selected targets of the Parkinson's disease (PD).Methods: PASS is a valuable software which is used in this study, to predict the anti-Parkinson activity of different compounds. Canonical simplified molecular-input line-entry system is used for the prediction of anti-Parkinson activity which is obtained from PubChem website. The predicted activity also compared with marketed compound like levodopa.Results: From the study, it was found that resveratrol was the only compound which has the activity on all the selected targets. On the other hand, stemazole and celastrol were found to have the least active compounds as both have the activity only on a single target. Conclusion:In this research work, we tried to compile the information regarding the PASS predicted anti-Parkinson activity of some important phytoconstituents. We found that resveratrol can be a target for further investigation in the development of drug therapy for PD.

show abstract

Neuroprotective and antidepressant-like effects of melatonin in a rotenone-induced Parkinson’s disease model in rats

Cited by 63 publications

References 53 publications

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases

Melatonin for Sleep Disorders in Patients with Neurodegenerative Diseases

Melatoninergic System in Parkinson’s Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms

Prediction of Anti-Parkinson Potential of Phytoconstituents Using Prediction of Activity Spectra of Substances Software

Contact Info

Product

Resources

About